O	0	9	Continued
O	10	19	Treatment
O	20	26	Effect
O	27	29	of
B-intervention	30	40	Zoledronic
I-intervention	41	45	Acid
O	46	52	Dosing
O	53	58	Every
O	59	61	12
O	62	64	vs
O	65	66	4
O	67	72	Weeks
O	73	75	in
O	76	81	Women
O	82	86	With
O	87	93	Breast
O	94	100	Cancer
O	101	111	Metastatic
O	112	114	to
O	115	119	Bone
O	119	120	:
O	121	124	The
O	125	133	OPTIMIZE
O	133	134	-
O	134	135	2
O	136	146	Randomized
O	147	155	Clinical
O	156	161	Trial
O	161	162	.

O	163	173	Zoledronic
O	174	178	acid
O	178	179	,
O	180	181	a
O	182	188	potent
O	189	203	bisphosphonate
O	203	204	,
O	205	207	is
O	208	216	commonly
O	217	229	administered
O	230	232	to
O	233	241	patients
O	242	246	with
O	247	251	bone
O	252	262	metastases
O	263	265	to
O	266	272	reduce
O	273	276	the
O	277	281	risk
O	282	284	of
O	285	293	skeletal
O	293	294	-
O	294	301	related
O	302	308	events
O	309	310	(
O	310	314	SREs
O	314	315	)
O	315	316	.

O	317	324	However
O	324	325	,
O	326	331	there
O	332	336	have
O	337	341	been
O	342	350	concerns
O	351	360	regarding
O	361	364	its
O	365	369	long
O	369	370	-
O	370	374	term
O	375	382	monthly
O	383	397	administration
O	397	398	.

O	399	401	To
O	402	409	examine
O	410	417	whether
O	418	428	zoledronic
O	429	433	acid
O	434	439	every
O	440	442	12
O	443	448	weeks
O	449	452	was
O	453	464	noninferior
O	465	467	to
O	468	478	zoledronic
O	479	483	acid
O	484	489	every
O	490	491	4
O	492	497	weeks
O	498	500	in
B-eligibility	501	509	patients
I-eligibility	510	514	with
I-eligibility	515	525	metastatic
I-eligibility	526	532	breast
I-eligibility	533	539	cancer
I-eligibility	540	544	that
I-eligibility	545	553	involved
I-eligibility	554	557	the
I-eligibility	558	562	bone
I-eligibility	563	566	who
I-eligibility	567	570	had
I-eligibility	571	581	previously
I-eligibility	582	590	received
I-eligibility	591	592	a
I-eligibility	593	601	standard
I-eligibility	602	608	dosing
I-eligibility	609	616	regimen
I-eligibility	617	619	of
I-eligibility	620	630	zoledronic
I-eligibility	631	635	acid
I-eligibility	636	639	and
I-eligibility	639	640	/
I-eligibility	640	642	or
I-eligibility	643	654	pamidronate
I-eligibility	655	663	disodium
O	663	664	.

O	665	673	OPTIMIZE
O	673	674	-
O	674	675	2
O	676	679	was
O	680	681	a
O	682	693	prospective
O	693	694	,
O	695	705	randomized
O	705	706	,
O	707	713	double
O	713	714	-
O	714	719	blind
O	719	720	,
O	721	732	multicenter
O	733	738	phase
O	739	740	3
O	741	746	trial
O	747	749	of
O	750	759	intention
O	759	760	-
O	760	762	to
O	762	763	-
O	763	768	treat
O	769	770	(
O	770	774	full
O	775	783	analysis
O	784	787	set
O	787	788	)
O	788	789	,
O	790	799	evaluable
O	800	801	(
O	801	804	per
O	805	813	protocol
O	813	814	)
O	814	815	,
O	816	819	and
O	820	826	safety
O	827	838	populations
O	838	839	.

O	840	848	Patients
O	849	853	were
O	854	864	randomized
O	865	866	(
O	866	867	1
O	867	868	:
O	868	869	1
O	869	870	)
O	871	873	to
O	874	881	receive
O	882	883	4
O	883	884	.
O	884	885	0
O	886	888	mg
O	889	891	of
O	892	903	intravenous
O	904	914	zoledronic
O	915	919	acid
O	920	925	every
O	926	927	4
O	928	930	or
O	931	936	every
O	937	939	12
O	940	945	weeks
O	946	950	with
B-control	951	958	placebo
O	959	962	for
O	963	970	interim
O	971	980	infusions
O	981	984	for
O	985	986	1
O	987	991	year
O	991	992	.

O	993	996	The
O	997	1002	study
O	1003	1006	was
O	1007	1016	conducted
O	1017	1019	at
O	1020	1023	102
O	1024	1032	clinical
O	1033	1038	trial
O	1039	1046	centers
O	1047	1049	in
O	1050	1053	the
B-location	1054	1060	United
I-location	1061	1067	States
O	1068	1072	from
O	1073	1078	March
O	1079	1080	3
O	1080	1081	,
O	1082	1086	2006
O	1086	1087	,
O	1088	1090	to
O	1091	1095	July
O	1096	1098	25
O	1098	1099	,
O	1100	1104	2013
O	1104	1105	.

O	1106	1110	Data
O	1111	1119	analysis
O	1120	1123	was
O	1124	1133	performed
O	1134	1138	from
O	1139	1146	October
O	1147	1148	7
O	1148	1149	,
O	1150	1154	2013
O	1154	1155	,
O	1156	1158	to
O	1159	1164	March
O	1165	1167	24
O	1167	1168	,
O	1169	1173	2014
O	1173	1174	.

O	1175	1178	The
O	1179	1184	study
O	1185	1195	randomized
B-total-participants	1196	1199	416
O	1200	1205	women
O	1206	1207	(
B-age	1207	1208	â‰¥
I-age	1208	1210	18
I-age	1211	1216	years
O	1217	1220	old
O	1220	1221	)
O	1222	1226	with
O	1227	1231	bone
O	1232	1242	metastases
O	1243	1247	from
O	1248	1254	breast
O	1255	1261	cancer
O	1262	1265	who
O	1266	1276	previously
O	1277	1285	received
O	1286	1287	9
O	1288	1290	or
O	1291	1295	more
O	1296	1301	doses
O	1302	1304	of
O	1305	1315	zoledronic
O	1316	1320	acid
O	1321	1324	and
O	1324	1325	/
O	1325	1327	or
O	1328	1339	pamidronate
O	1340	1346	during
O	1347	1350	the
O	1351	1356	first
O	1357	1359	10
O	1360	1362	to
O	1363	1365	15
O	1366	1372	months
O	1373	1375	of
O	1376	1383	therapy
O	1383	1384	.

O	1385	1388	The
O	1389	1396	primary
O	1397	1400	end
O	1401	1406	point
O	1407	1410	was
O	1411	1414	the
B-outcome-Measure	1415	1425	proportion
I-outcome-Measure	1426	1428	of
I-outcome-Measure	1429	1437	patients
I-outcome-Measure	1438	1442	with
I-outcome-Measure	1443	1444	1
I-outcome-Measure	1445	1447	or
I-outcome-Measure	1448	1452	more
I-outcome-Measure	1453	1456	SRE
I-outcome-Measure	1457	1459	on
I-outcome-Measure	1460	1465	study
I-outcome-Measure	1466	1467	(
I-outcome-Measure	1467	1470	SRE
I-outcome-Measure	1471	1475	rate
I-outcome-Measure	1475	1476	)
O	1476	1477	.

O	1478	1481	The
O	1482	1485	key
O	1486	1495	secondary
O	1496	1499	end
O	1500	1506	points
O	1507	1515	included
B-outcome-Measure	1516	1520	time
I-outcome-Measure	1521	1523	to
I-outcome-Measure	1524	1529	first
I-outcome-Measure	1530	1533	SRE
O	1534	1537	and
B-outcome-Measure	1538	1546	skeletal
I-outcome-Measure	1547	1556	morbidity
I-outcome-Measure	1557	1561	rate
I-outcome-Measure	1562	1563	(
I-outcome-Measure	1563	1566	SMR
I-outcome-Measure	1566	1567	)
O	1567	1568	.

O	1569	1570	A
O	1571	1576	total
O	1577	1579	of
B-total-participants	1580	1583	416
O	1584	1589	women
O	1590	1594	were
O	1595	1605	randomized
O	1605	1606	:
B-intervention-participants	1607	1610	200
O	1611	1619	patients
O	1620	1628	received
O	1629	1639	zoledronic
O	1640	1644	acid
O	1645	1650	every
O	1651	1652	4
O	1653	1658	weeks
O	1659	1660	(
O	1660	1664	mean
O	1665	1666	[
O	1666	1668	SD
O	1668	1669	]
O	1670	1673	age
O	1673	1674	,
O	1675	1677	59
O	1677	1678	.
O	1678	1679	2
O	1680	1681	[
O	1681	1683	11
O	1683	1684	.
O	1684	1685	1
O	1685	1686	]
O	1687	1692	years
O	1692	1693	;
O	1694	1697	173
O	1698	1702	were
B-ethinicity	1703	1708	white
O	1709	1710	[
O	1710	1712	86
O	1712	1713	.
O	1713	1714	5
O	1714	1715	%
O	1715	1716	]
O	1716	1717	)
O	1717	1718	,
B-control-participants	1719	1722	203
O	1723	1731	patients
O	1732	1740	received
O	1741	1751	zoledronic
O	1752	1756	acid
O	1757	1762	every
O	1763	1765	12
O	1766	1771	weeks
O	1772	1773	(
O	1773	1777	mean
O	1778	1779	[
O	1779	1781	SD
O	1781	1782	]
O	1783	1786	age
O	1786	1787	,
O	1788	1790	58
O	1790	1791	.
O	1791	1792	6
O	1793	1794	[
O	1794	1796	11
O	1796	1797	.
O	1797	1798	2
O	1798	1799	]
O	1800	1805	years
O	1805	1806	;
O	1807	1810	178
O	1811	1815	were
B-ethinicity	1816	1821	white
O	1822	1823	[
O	1823	1825	87
O	1825	1826	.
O	1826	1827	7
O	1827	1828	%
O	1828	1829	]
O	1829	1830	)
O	1830	1831	,
O	1832	1835	and
B-control-participants	1836	1838	13
O	1839	1847	patients
O	1848	1856	received
O	1857	1864	placebo
O	1865	1866	(
O	1866	1870	mean
O	1871	1872	[
O	1872	1874	SD
O	1874	1875	]
O	1876	1879	age
O	1879	1880	,
O	1881	1883	60
O	1883	1884	.
O	1884	1885	8
O	1886	1887	[
O	1887	1889	12
O	1889	1890	.
O	1890	1891	2
O	1891	1892	]
O	1893	1898	years
O	1898	1899	;
O	1900	1902	13
O	1903	1907	were
B-ethinicity	1908	1913	white
O	1914	1915	[
O	1915	1918	100
O	1918	1919	%
O	1919	1920	]
O	1920	1921	)
O	1921	1922	.

O	1923	1931	Baseline
O	1932	1947	characteristics
O	1948	1952	were
O	1953	1960	similar
O	1961	1963	in
O	1964	1968	both
O	1969	1979	zoledronic
O	1980	1984	acid
O	1985	1994	treatment
O	1995	1999	arms
O	1999	2000	.

O	2001	2006	After
O	2007	2008	1
O	2009	2013	year
O	2014	2016	of
O	2017	2023	follow
O	2023	2024	-
O	2024	2026	up
O	2026	2027	,
B-outcome	2028	2032	SREs
O	2033	2041	occurred
O	2042	2044	in
B-cv-bin-abs	2045	2047	44
O	2048	2056	patients
O	2057	2058	(
B-cv-bin-percent	2058	2060	22
I-cv-bin-percent	2060	2061	.
I-cv-bin-percent	2061	2062	0
I-cv-bin-percent	2062	2063	%
O	2063	2064	)
O	2065	2067	in
O	2068	2071	the
O	2072	2082	zoledronic
O	2083	2087	acid
O	2088	2093	every
O	2094	2095	4
O	2096	2101	weeks
O	2102	2107	group
O	2108	2111	and
B-iv-bin-abs	2112	2114	47
O	2115	2123	patients
O	2124	2125	(
B-iv-bin-percent	2125	2127	23
I-iv-bin-percent	2127	2128	.
I-iv-bin-percent	2128	2129	2
I-iv-bin-percent	2129	2130	%
O	2130	2131	)
O	2132	2134	in
O	2135	2138	the
O	2139	2149	zoledronic
O	2150	2154	acid
O	2155	2160	every
O	2161	2163	12
O	2164	2169	weeks
O	2170	2175	group
O	2176	2177	(
O	2177	2189	proportional
O	2190	2200	difference
O	2201	2203	of
O	2204	2205	-
O	2205	2206	1
O	2206	2207	.
O	2207	2208	2
O	2208	2209	%
O	2209	2210	;
O	2211	2212	1
O	2212	2213	-
O	2213	2218	sided
O	2219	2221	97
O	2221	2222	.
O	2222	2223	5
O	2223	2224	%
O	2225	2227	CI
O	2228	2233	bound
O	2234	2236	of
O	2237	2240	the
O	2241	2251	difference
O	2252	2254	in
O	2255	2258	SRE
O	2259	2263	rate
O	2264	2271	between
O	2272	2276	arms
O	2276	2277	,
O	2278	2279	-
O	2279	2280	9
O	2280	2281	.
O	2281	2282	8
O	2282	2283	%
O	2283	2284	;
O	2285	2299	noninferiority
O	2300	2301	P
O	2302	2303	=
O	2304	2305	.
O	2305	2307	02
O	2307	2308	)
O	2308	2309	.

O	2310	2313	The
B-outcome	2314	2318	time
I-outcome	2319	2321	to
I-outcome	2322	2327	first
I-outcome	2328	2331	SRE
O	2332	2339	between
O	2340	2349	treatment
O	2350	2356	groups
O	2357	2360	was
O	2361	2364	not
O	2365	2378	statistically
O	2379	2392	significantly
O	2393	2402	different
O	2403	2404	(
O	2404	2410	hazard
O	2411	2416	ratio
O	2417	2418	[
O	2418	2420	HR
O	2420	2421	]
O	2421	2422	,
O	2423	2424	1
O	2424	2425	.
O	2425	2427	06
O	2427	2428	;
O	2429	2431	95
O	2431	2432	%
O	2433	2435	CI
O	2435	2436	,
O	2437	2438	0
O	2438	2439	.
O	2439	2441	70
O	2441	2442	-
O	2442	2443	1
O	2443	2444	.
O	2444	2446	60
O	2446	2447	;
O	2448	2449	P
O	2450	2451	=
O	2452	2453	.
O	2453	2455	79
O	2455	2456	)
O	2456	2457	.

O	2458	2461	The
B-outcome	2462	2466	mean
I-outcome	2467	2468	(
I-outcome	2468	2470	SD
I-outcome	2470	2471	)
I-outcome	2472	2475	SMR
O	2476	2479	was
B-cv-cont-mean	2480	2481	0
I-cv-cont-mean	2481	2482	.
I-cv-cont-mean	2482	2484	46
O	2485	2486	(
B-cv-cont-sd	2486	2487	1
I-cv-cont-sd	2487	2488	.
I-cv-cont-sd	2488	2490	06
O	2490	2491	)
O	2492	2494	vs
B-iv-cont-mean	2495	2496	0
I-iv-cont-mean	2496	2497	.
I-iv-cont-mean	2497	2499	50
O	2500	2501	(
B-iv-cont-sd	2501	2502	1
I-iv-cont-sd	2502	2503	.
I-iv-cont-sd	2503	2505	50
O	2505	2506	)
O	2507	2513	events
O	2514	2517	per
O	2518	2522	year
O	2523	2525	in
O	2526	2529	the
O	2530	2535	every
O	2536	2537	4
O	2538	2543	weeks
O	2544	2546	vs
O	2547	2552	every
O	2553	2555	12
O	2556	2561	weeks
O	2562	2568	groups
O	2569	2570	(
O	2570	2571	P
O	2572	2573	=
O	2574	2575	.
O	2575	2577	85
O	2577	2578	)
O	2578	2579	.

O	2580	2583	The
B-outcome	2584	2590	safety
I-outcome	2591	2599	profiles
O	2600	2602	of
O	2603	2606	the
O	2607	2612	every
O	2613	2614	4
O	2615	2620	weeks
O	2621	2624	and
O	2625	2630	every
O	2631	2633	12
O	2634	2639	weeks
O	2640	2646	groups
O	2647	2651	were
O	2652	2662	comparable
O	2662	2663	,
O	2664	2668	with
B-cv-bin-abs	2669	2672	189
O	2673	2681	patients
O	2682	2683	(
B-cv-bin-percent	2683	2685	95
I-cv-bin-percent	2685	2686	.
I-cv-bin-percent	2686	2687	5
I-cv-bin-percent	2687	2688	%
O	2688	2689	)
O	2690	2692	in
O	2693	2696	the
O	2697	2702	every
O	2703	2704	4
O	2705	2710	weeks
O	2711	2716	group
O	2717	2723	having
O	2724	2726	at
O	2727	2732	least
O	2733	2734	1
O	2735	2742	adverse
O	2743	2748	event
O	2749	2757	compared
O	2758	2762	with
B-iv-bin-abs	2763	2766	189
O	2767	2768	(
B-iv-bin-percent	2768	2770	93
I-iv-bin-percent	2770	2771	.
I-iv-bin-percent	2771	2772	5
I-iv-bin-percent	2772	2773	%
O	2773	2774	)
O	2775	2777	in
O	2778	2781	the
O	2782	2787	every
O	2788	2790	12
O	2791	2796	weeks
O	2797	2802	group
O	2802	2803	.

O	2804	2807	The
O	2808	2813	every
O	2814	2816	12
O	2817	2822	weeks
O	2823	2830	regimen
O	2831	2833	of
O	2834	2844	zoledronic
O	2845	2849	acid
O	2850	2853	was
O	2854	2865	noninferior
O	2866	2868	to
O	2869	2872	the
O	2873	2878	every
O	2879	2880	4
O	2881	2886	weeks
O	2887	2894	regimen
O	2895	2898	for
O	2899	2902	the
O	2903	2913	proportion
O	2914	2916	of
O	2917	2925	patients
O	2926	2938	experiencing
O	2939	2940	1
O	2941	2943	or
O	2944	2948	more
O	2949	2952	SRE
O	2952	2953	.

O	2954	2959	These
O	2960	2967	results
O	2968	2971	may
O	2972	2976	have
O	2977	2978	a
O	2979	2990	substantial
O	2991	3000	influence
O	3001	3003	on
O	3004	3011	current
O	3012	3020	clinical
O	3021	3029	practice
O	3030	3033	for
O	3034	3043	treatment
O	3044	3046	of
O	3047	3055	patients
O	3056	3060	with
O	3061	3065	bone
O	3066	3076	metastasis
O	3077	3081	from
O	3082	3088	breast
O	3089	3095	cancer
O	3095	3096	.
O	3097	3111	clinicaltrials
O	3111	3112	.
O	3112	3115	gov
O	3116	3126	Identifier
O	3126	3127	:
O	3128	3139	NCT00320710
O	3139	3140	.
